10x Genomics annual gross margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
10x Genomics's gross margin was 69.05% for fiscal 2025.
View full 10x Genomics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 69.05% | +1.19 pp |
| 2024 | 2024-12-31 | 67.86% | +1.71 pp |
| 2023 | 2023-12-31 | 66.15% | −10.53 pp |
| 2022 | 2022-12-31 | 76.69% | −8.21 pp |
| 2021 | 2021-12-31 | 84.89% | +4.46 pp |
| 2020 | 2020-12-31 | 80.44% | +5.26 pp |
| 2019 | 2019-12-31 | 75.18% | −5.23 pp |
| 2018 | 2018-12-31 | 80.41% | −4.73 pp |
| 2017 | 2017-12-31 | 85.14% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 74.48% | +2.14 pp |
| Q1 2026 | 2026-03-31 | 70.39% | +2.31 pp |
| Q4 2025 | 2025-12-31 | 68.09% | +0.85 pp |
| Q3 2025 | 2025-09-30 | 67.32% | −2.84 pp |
| Q2 2025 | 2025-06-30 | 72.34% | +4.27 pp |
| Q1 2025 | 2025-03-31 | 68.08% | +2.19 pp |
| Q4 2024 | 2024-12-31 | 67.24% | +4.30 pp |
| Q3 2024 | 2024-09-30 | 70.16% | +7.98 pp |
| Q2 2024 | 2024-06-30 | 68.07% | +0.22 pp |
| Q1 2024 | 2024-03-31 | 65.89% | −7.38 pp |
| Q4 2023 | 2023-12-31 | 62.93% | −13.50 pp |
| Q3 2023 | 2023-09-30 | 62.18% | −14.65 pp |
| Q2 2023 | 2023-06-30 | 67.85% | −7.98 pp |
| Q1 2023 | 2023-03-31 | 73.27% | −4.48 pp |
| Q4 2022 | 2022-12-31 | 76.43% | −4.34 pp |
| Q3 2022 | 2022-09-30 | 76.82% | −3.61 pp |
| Q2 2022 | 2022-06-30 | 75.83% | −19.93 pp |
| Q1 2022 | 2022-03-31 | 77.75% | −6.13 pp |
| Q4 2021 | 2021-12-31 | 80.77% | −2.39 pp |
| Q3 2021 | 2021-09-30 | 80.43% | +0.50 pp |
| Q2 2021 | 2021-06-30 | 95.76% | +19.19 pp |
| Q1 2021 | 2021-03-31 | 83.88% | +4.89 pp |
| Q4 2020 | 2020-12-31 | 83.16% | +5.18 pp |
| Q3 2020 | 2020-09-30 | 79.93% | +5.22 pp |
| Q2 2020 | 2020-06-30 | 76.57% | +3.45 pp |
| Q1 2020 | 2020-03-31 | 78.99% | +5.05 pp |
| Q4 2019 | 2019-12-31 | 77.98% | −7.71 pp |
| Q3 2019 | 2019-09-30 | 74.71% | — |
| Q2 2019 | 2019-06-30 | 73.12% | — |
| Q1 2019 | 2019-03-31 | 73.94% | — |
| Q3 2018 | 2018-09-30 | 85.68% | — |
Over the last five reported fiscal years, 10x Genomics's gross margin decreased from 80.44% to 69.05%, a change of −11.38 percentage points. The latest reported quarter, Q2 2026, shows 74.48%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review 10x Genomics filings at SEC.gov ↗